Confirmation Agreement Regarding License and Development Rights between BioDelivery Sciences, Arius Entities, and Meda AB
BioDelivery Sciences International, Inc., Arius Pharmaceuticals, Inc., and Arius Two, Inc. confirm to Meda AB that they will not amend, modify, or terminate any third-party agreements in a way that would affect Meda's rights under their License and Development Agreement, unless Meda's rights are preserved. This ensures Meda's interests under the agreement remain protected and uninterrupted.
Exhibit 10.30
September 5, 2007
Meda AB
Box 906
Pipers vag 2A
17009
Solna, Sweden
Attention: Anders Lonners, CEO
Dear Anders:
This letter will confirm our agreement with Meda that neither BDSI, Arius nor Arius Two will take any action to amend, modify or terminate any agreement with a third party which would cause a termination or modification of Meda’s rights under the License and Development Agreement dated as of the date hereof, and each document, instrument, agreement, license and/or sublicense related thereto, unless provision is made for Meda’s rights under such License and Development Agreement and such related documents to continue undisturbed.
| Very Truly Yours, | ||
| BioDelivery Sciences International, Inc. | ||
| By: | /s/ Mark A. Sirgo, President and CEO | |
| Arius Pharmaceuticals, Inc. | ||
| By: | /s/ Mark A. Sirgo, President and CEO | |
| Arius Two, Inc. | ||
| By: | /s/ Mark A. Sirgo, President and CEO | |
